Browsing by Author "Tokyo Shinagawa Hospital"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    PublicationMetadata only
    Glycan engineering of the sars-cov-2 receptor-binding domain elicits cross-neutralizing antibodies for sars-related viruses
    (2021-12-06) Ryo Shinnakasu; Shuhei Sakakibara; Hiromi Yamamoto; Po Hung Wang; Saya Moriyama; Nicolas Sax; Chikako Ono; Atsushi Yamanaka; Yu Adachi; Taishi Onodera; Takashi Sato; Masaharu Shinkai; Ryosuke Suzuki; Yoshiharu Matsuura; Noritaka Hashii; Yoshimasa Takahashi; Takeshi Inoue; Kazuo Yamashita; Tomohiro Kurosaki; Faculty of Tropical Medicine, Mahidol University; WPI Immunology Frontier Research Center, Osaka University; National Institute of Infectious Diseases; Research Institute for Microbial Diseases; Riken Research Center for Allergy and Immunology; Osaka University; National Institute of Health Sciences Tokyo; Tokyo Shinagawa Hospital; National Institute of Infection Diseases
    Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD–specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.